Valuation of an intangible asset (technology / R&D)

Hi,

How would you estimate the value of an intangible asset, more specifically an R&D formulation?

I represent an industrial buyer, who is considering to acquire an R&D formulation from a competitor. The products can be sold to our clients current customers, but will require some minor modifications. The estimated product life cycle of the technology is estimated by our client to ~7 years. The R&D formulation / products are not commercialized yet, and has no brand attached to it.

What methods would you use to estimate the value of such technology? The relief from royalty method appears obvious, but can I sanity check the value with other methods?

Thanks!

 

DCF. I would imagine this would be very similar to valuing a clinical stage drug in pharma/biotech. Build out a revenue projection, incorporate costs associated with those revenues and then back into what you can pay upfront for the R&D formulation to achieve a given hurdle rate (or if you have a value already, your estimated IRR). Can also adjust for probability of success if you are not 100% sure it will make it to market after modification.

 

This is something that could be a very complex exercise and you may want to seek the help of a Big 4 Valuation professional (I worked in valuations previously, so I have an idea).

When you are talking about taking contributing asset charges, you are not using the relief from royalty method but the excess earnings method. The premise of the excess earnings is you are taking charges for things like fixed assets, nwc, trademarks and any other assets (intangible or tangible) that the R&D may need to commercialize the product or progress the technology. The idea is once you take out all the other charges, you are then down to the pure intangible asset value.

Also, if you are R&D you will most likely need to split out the R&D into Developed Technology, IPR&D and Future Technology (typically grouped with goodwill). Each split will be amortized over different lives.

This is a high-level overview that can get very complex and subjective, that's why I would suggest a professional if you think this is something that could be material.

 

First off, I'm no expert, but I did 2-3 VC deals where IP was factored in and if we didn't believe we had rock solid IP, we couldn't do the deal.

If you have the money and this ins't just a personal investment, I would seriously hire a good IP lawyer to do a patent search. Seriously, whether they have provisional or issued patents, it doesn't mean it's safe necessarily. In a lawsuit a judge can score a patent too comprehensive and not valid for all areas it covers. Understand that may sound like an oxymoron, but essentially my understanding is the way the patent applications are written will determine a lot of it's ability to be defended. For example, a patent that covers the application of a technology for it's entire industry likely could lose where as 5 patents issued for the same thing in each industry sub-vertical may stand a better chance.

Now that's just stuff I've learned a little form doing some deals and working for a former head of R&D at a fortune 500. When it came to valuing IP, I don't have a great methodology. Thinking about my deals (more science, less tech), I'm thinking if any of those deals failed, we could probably still sell the IP to a Fortune 500 for 1.0x - 1.5x MoM.

my $0.02

"If you want to succeed in this life, you need to understand that duty comes before rights and that responsibility precedes opportunity."
 

IAS 38 forbids certain categories of intangibles to be recognized as assets in the balance sheet, and for those that are allowed an extensive set of requirements must be met. Still, you can have intangibles in the balance sheet if they meet the requirements. Post acquisition you will have goodwill to deal with (IFRS 3), which will give you some (better) picture of the (unidentifiable) intangibles value of the acquired entity. Given that goodwill must be reviewed for impairments periodically (annually under IFRS), they will to some extent represent the valuation of the intangibles of the acquired entity with some accuracy (from the point of view of the auditor of the company, at least). If the acquired entity wasn't acquired, their intangible assets would only be valued before (in the balance sheet) to the extent they met the requirements for that to happen.

"Never believe in anything until it has been officially denied"
 

The intangibles that are usually marked to "Fair Value" as part of an acquisition are often items that have been expensed over time (and therefore not capitalized). Eg, your salespeople create customer lists and maintain relationships as part of their jobs (salary expense), but "customer lists" may be allocated some value as part of acquisition accounting.

To prevent fraud, everyday accounting standards have relatively strict thresholds for capitalization (if you're building a factory, capitalize it as an asset, but if you're marketing, isn't that just an expense?), but acquisition requires recognition of acquired assets at FV -- so these intangibles that the business has been building up over time will get recognized on the acquirer's balance sheet. Make sense?

 

Vel provident in ea iste nisi. Accusantium et porro amet.

Ex ab aut nobis amet ut vero beatae. Iure a voluptatem laudantium tempora. Deserunt non quis ducimus fugit. Quia ab omnis quis ullam dolor et. Eos aut porro quam facilis. Ipsa dolorem non quaerat voluptas.

Optio totam praesentium sed ut. Voluptatibus assumenda illo asperiores culpa dolorem a. Sit architecto repudiandae ut expedita. Necessitatibus tempore quia sapiente et temporibus dolorem ut. Est quo odio pariatur ut aut et fugit.

Qui natus pariatur velit et corporis harum commodi. Placeat rerum esse et laborum cupiditate eum. In et corporis fuga assumenda.

"Never believe in anything until it has been officially denied"

Career Advancement Opportunities

April 2024 Investment Banking

  • Jefferies & Company 02 99.4%
  • Goldman Sachs 19 98.8%
  • Harris Williams & Co. New 98.3%
  • Lazard Freres 02 97.7%
  • JPMorgan Chase 03 97.1%

Overall Employee Satisfaction

April 2024 Investment Banking

  • Harris Williams & Co. 18 99.4%
  • JPMorgan Chase 10 98.8%
  • Lazard Freres 05 98.3%
  • Morgan Stanley 07 97.7%
  • William Blair 03 97.1%

Professional Growth Opportunities

April 2024 Investment Banking

  • Lazard Freres 01 99.4%
  • Jefferies & Company 02 98.8%
  • Goldman Sachs 17 98.3%
  • Moelis & Company 07 97.7%
  • JPMorgan Chase 05 97.1%

Total Avg Compensation

April 2024 Investment Banking

  • Director/MD (5) $648
  • Vice President (19) $385
  • Associates (87) $260
  • 3rd+ Year Analyst (14) $181
  • Intern/Summer Associate (33) $170
  • 2nd Year Analyst (66) $168
  • 1st Year Analyst (205) $159
  • Intern/Summer Analyst (146) $101
notes
16 IB Interviews Notes

“... there’s no excuse to not take advantage of the resources out there available to you. Best value for your $ are the...”

Leaderboard

1
redever's picture
redever
99.2
2
Betsy Massar's picture
Betsy Massar
99.0
3
BankonBanking's picture
BankonBanking
99.0
4
Secyh62's picture
Secyh62
99.0
5
kanon's picture
kanon
98.9
6
GameTheory's picture
GameTheory
98.9
7
CompBanker's picture
CompBanker
98.9
8
dosk17's picture
dosk17
98.9
9
numi's picture
numi
98.8
10
Kenny_Powers_CFA's picture
Kenny_Powers_CFA
98.8
success
From 10 rejections to 1 dream investment banking internship

“... I believe it was the single biggest reason why I ended up with an offer...”